Human Genome Research
The promise of genomics in relation to human disease is being held back by the inability to resolve large structural variations. Existing technologies, including next-generation sequencing (NGS), diagnose less than 50% of patients with genetic disorders.1,2 Bionano genome mapping offers unmatched structural variation discovery, making Saphyr™ essential to human genome and translational research.
Large structural variants such as deletions, duplications, inversions and translocations are extensively present, and many are known to affect biological functions and cause disease, including cancers and developmental disorders.
Precision medicine initiatives require accurate analyses of human genomes. While improvements in sequencing technology have allowed for spectacular progress in the detection of single nucleotide changes, the analysis of larger structural variations has remained ineffective. Standard methodologies for detecting structural variations have significant limitations. Chromosomal microarray is insensitive to novel insertions, mobile element insertions, many low copy repeats, and all balanced translocations and inversions. In addition, short-read sequencing methods have low sensitivity to most large variants and often fail in repetitive regions or those with high GC-content. Long-read sequencing has better sensitivity for heterozygous structural variations but is unable to span larger repetitive regions.
Saphyr fills in what’s missing from sequencing-based and other approaches with unparalleled sensitivity for large structural variations from 500 bp to megabase pair lengths.
- 99% sensitivity for homozygous insertions/deletions larger than 500 base pairs
- 95% sensitivity for heterozygous insertions/deletions larger than 500 base pairs
- 95% sensitivity for balanced and unbalanced translocations larger than 50,000 base pairs
- 99% sensitivity for inversions larger than 30,000 base pairs
- 97% sensitivity for duplications larger than 30,000 base pairs
- 97% sensitivity for copy number variants larger than 500,000 base pairs
For mosaic samples or heterogeneous cancer samples, Saphyr detects all types of structural variants down to 5% Variant Allele Fraction. Saphyr provides this performance typically with a false positive rate of less than 2%. Saphyr also calls repeats and complex rearrangements.
Unlike NGS, which algorithmically infers structural variants from fragmented DNA data, Bionano optical genome mapping directly observes structural variations by linearizing and imaging DNA in its native state using massively parallel NanoChannels. This direct observation results in some of the longest read lengths in genomic research. As a result, Bionano next-generation mapping yields hundreds of times more contiguous assembly than sequencing technologies alone can provide.
See below for publications, white papers and other resources regarding Bionano genome mapping in human genome and translational research.
- Undiagnosed Genetic Disorders – close the diagnosis gap by detecting large structural events missed by NGS
- Gene discovery and therapy development – identify genes of interest, their locations and how structural variations impact them to inform effective therapy development
- Cancer – detect and visualize large rearrangements occurring in cancer genomes
- Cell line studies – monitor genomic integrity of cell lines and off-target effects of genetic engineering
- Reference genome assembly – perform de novo assembly and correct assemblies generated by sequencing-based systems
- Science 2021
- medRxiv 2021
- bioRxiv 2021
- November 18, 2020
- Rapid Isolation of high quality ultra-high molecular weight (UHMW) genomic DNA (gDNA) from blood, bone marrow aspirates (BMAs) and fresh frozen human tumorsNovember 18, 2020
- February, 2020
- Miller DT, A. M. (2010). Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet, 86 (5), 749-64.
- Hane Lee, J. L.-R.-A. (2014). Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders. JAMA, 312 (18), 1880-1887.